A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.

Slides:



Advertisements
Similar presentations
Volume 68, Issue 6, Pages (December 2015)
Advertisements

Volume 164, Issue 6, Pages (December 2000)
The PSA Era is not Over for Prostate Cancer
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Volume 65, Issue 6, Pages (June 2014)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 72, Issue 5, Pages (November 2017)
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Volume 61, Issue 6, Pages (June 2012)
Volume 71, Issue 2, Pages (February 2017)
Volume 74, Issue 2, Pages (August 2018)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Volume 65, Issue 6, Pages (June 2014)
Advances in the Treatment of Metastatic Prostate Cancer
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 56, Issue 2, Pages (August 2009)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer  Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.
Volume 72, Issue 2, Pages (August 2017)
Volume 65, Issue 1, Pages (January 2014)
Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward  Takuma Uo, Cynthia Sprenger  European Urology 
Volume 71, Issue 1, Pages 1-3 (January 2017)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Volume 66, Issue 3, Pages (September 2014)
Obesity and Prostate Cancer: A Role for Adipokines
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
Counselling the Prostate Cancer Patient
The Mutational Landscape of Prostate Cancer
Volume 70, Issue 4, Pages (October 2016)
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Leonard S. Marks, Jiaoti Huang  European Urology 
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 68, Issue 6, Pages e134-e135 (December 2015)
Volume 74, Issue 2, Pages (August 2018)
Volume 67, Issue 1, Pages (January 2015)
Volume 73, Issue 1, Pages 4-8 (January 2018)
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 6, Pages (June 2008)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 71, Issue 6, Pages (June 2017)
Testicular Cancer Variations in Time and Space in Europe
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 66, Issue 6, Pages (December 2014)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
European Urology is “Your” Journal
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Improving Flexibility and Quality of Life for Your Patients: A Must?
William G. Nelson, Michael C. Haffner, Srinivasan Yegnasubramanian 
Volume 53, Issue 6, Pages (June 2008)
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Volume 53, Issue 2, Pages (February 2008)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Presentation transcript:

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer  Archana Anantharaman, Terence W. Friedlander  European Urology  Volume 68, Issue 6, Pages 946-948 (December 2015) DOI: 10.1016/j.eururo.2015.07.053 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Representation of splicing of androgen receptor (AR) to full length, wild-type AR versus truncated, constitutively active splice variant AR-V7. Absence of LBD in AR-V7 prevents activity of available AR targeted agents. AA=antiandrogen therapy (eg, bicalutamide, nilutamide, flutamide, enzalutamide); AR=androgen receptor; DBD=DNA binding domain; DHT=dihydrotestosterone; LBD=ligand binding domain; NTD=N-terminal domain. European Urology 2015 68, 946-948DOI: (10.1016/j.eururo.2015.07.053) Copyright © 2015 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.